Matches in Wikidata for { <http://www.wikidata.org/entity/Q91349813> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q91349813 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q91349813 description "scientific article published on 27 February 2019" @default.
- Q91349813 description "wetenschappelijk artikel" @default.
- Q91349813 description "наукова стаття, опублікована в лютому 2019" @default.
- Q91349813 name "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 name "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 type Item @default.
- Q91349813 label "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 label "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 prefLabel "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 prefLabel "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-" @default.
- Q91349813 P1433 Q91349813-18A9CBBE-811E-4E7D-9CCD-DA0719C04110 @default.
- Q91349813 P1476 Q91349813-5D400842-96D9-4351-B673-65D03BA33CC4 @default.
- Q91349813 P2093 Q91349813-12F10EC7-2F20-4DAD-AE75-8B4EA9F499DE @default.
- Q91349813 P2093 Q91349813-22ED6CBB-9B6E-4DCE-AFE1-A36931843534 @default.
- Q91349813 P2093 Q91349813-4AC855E5-871A-437D-BA56-244989CDEF4D @default.
- Q91349813 P2093 Q91349813-5D19E9D6-1997-4C96-81BF-FB0F6DBD59D2 @default.
- Q91349813 P2093 Q91349813-6180038B-B9A3-4846-A8CC-24481E80525C @default.
- Q91349813 P2093 Q91349813-65279787-BB17-4856-B393-FC838A82C9FB @default.
- Q91349813 P2093 Q91349813-72916F06-D74F-453D-817C-64F34EE5EEDD @default.
- Q91349813 P2093 Q91349813-93618BBC-8504-41B5-9BBB-90E4CD5589C1 @default.
- Q91349813 P2093 Q91349813-9950AA3A-B3CB-4B6E-BA44-88D41CEC4FF9 @default.
- Q91349813 P2093 Q91349813-EBFCBC15-61BE-4BCC-AB51-D7AC7948E3DA @default.
- Q91349813 P2093 Q91349813-F124DF75-100C-44D8-8442-ECE11BCF3C3C @default.
- Q91349813 P2860 Q91349813-B7BABD59-D2D3-41DC-99A7-0B5E7B4CC2CA @default.
- Q91349813 P304 Q91349813-3E0D6931-0430-43B5-A668-0A7FB5141A06 @default.
- Q91349813 P31 Q91349813-CE0986F3-89DE-4CF0-88AB-0496EE72E69A @default.
- Q91349813 P356 Q91349813-FEBF4943-4341-44FF-AE7D-68F63232CFF4 @default.
- Q91349813 P407 Q91349813-AF5F290D-3E51-41F0-9F30-AA47FDCF07E0 @default.
- Q91349813 P433 Q91349813-141BE6D1-E64A-4840-8286-F2316FCA12CC @default.
- Q91349813 P478 Q91349813-9A44910E-38F5-4397-B617-083CB2E094E9 @default.
- Q91349813 P50 Q91349813-7F8E34D5-1E70-4AB0-87B1-941B43E99E24 @default.
- Q91349813 P50 Q91349813-AA1EE347-56D4-42F8-8641-BB4CA10C7B80 @default.
- Q91349813 P577 Q91349813-912FFD21-2443-4894-AEEE-F09417F5EEA7 @default.
- Q91349813 P698 Q91349813-D6FCCCC7-5092-43F4-8332-AFA00AE33C12 @default.
- Q91349813 P921 Q91349813-5E1BB8F4-7CC2-432D-BDF6-A143D62B1264 @default.
- Q91349813 P921 Q91349813-69B16C82-C25E-4456-8F7D-06457E245FEF @default.
- Q91349813 P921 Q91349813-763A76A1-0CCA-45D4-9B1D-349EA685A582 @default.
- Q91349813 P921 Q91349813-D0757369-D714-499D-B61B-96BFDA1366EE @default.
- Q91349813 P356 IJC.32188 @default.
- Q91349813 P698 30720867 @default.
- Q91349813 P1433 Q332492 @default.
- Q91349813 P1476 "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients" @default.
- Q91349813 P2093 "Eunjin Lee" @default.
- Q91349813 P2093 "Hae Hyun Jung" @default.
- Q91349813 P2093 "Jee Hyun Kim" @default.
- Q91349813 P2093 "Ji-Yeon Kim" @default.
- Q91349813 P2093 "Joohyuk Sohn" @default.
- Q91349813 P2093 "Keun Seok Lee" @default.
- Q91349813 P2093 "Ki Hyeong Lee" @default.
- Q91349813 P2093 "Kyung Hae Jung" @default.
- Q91349813 P2093 "Kyung-Hun Lee" @default.
- Q91349813 P2093 "Kyunghee Park" @default.
- Q91349813 P2093 "Woong-Yang Park" @default.
- Q91349813 P2860 Q34880994 @default.
- Q91349813 P304 "1669-1678" @default.
- Q91349813 P31 Q13442814 @default.
- Q91349813 P356 "10.1002/IJC.32188" @default.
- Q91349813 P407 Q1860 @default.
- Q91349813 P433 "6" @default.
- Q91349813 P478 "145" @default.
- Q91349813 P50 Q58821370 @default.
- Q91349813 P50 Q89441271 @default.
- Q91349813 P577 "2019-02-27T00:00:00Z" @default.
- Q91349813 P698 "30720867" @default.
- Q91349813 P921 Q27088426 @default.
- Q91349813 P921 Q415271 @default.
- Q91349813 P921 Q42824440 @default.
- Q91349813 P921 Q864574 @default.